Vinva Investment Management Ltd Sells 2,848 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Vinva Investment Management Ltd decreased its position in Royalty Pharma plc (NASDAQ:RPRX) by 14.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 17,098 shares of the biopharmaceutical company’s stock after selling 2,848 shares during the quarter. Vinva Investment Management Ltd’s holdings in Royalty Pharma were worth $433,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in RPRX. Brooklyn Investment Group lifted its position in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP lifted its position in Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 877 shares in the last quarter. Riverview Trust Co lifted its position in Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,186 shares in the last quarter. Fifth Third Bancorp lifted its position in Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its position in Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 1,003 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 0.6 %

NASDAQ RPRX opened at $33.70 on Friday. The company has a market cap of $19.43 billion, a PE ratio of 23.24, a PEG ratio of 2.31 and a beta of 0.47. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The stock has a 50 day moving average of $32.25 and a 200-day moving average of $28.72.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities research analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.61%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Analysts Set New Price Targets

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.